Search results for "macrophage"

showing 10 items of 781 documents

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

2008

AbstractThe tyrosine kinase inhibitors sorafenib and sunitinib are approved for the treatment of patients with malignant diseases. To analyze the possible use of these compounds in combination with immunotherapeutic approaches, we analyzed the effects of both inhibitors on the immunostimulatory capacity of human dendritic cells (DCs) and the induction of primary immune responses in vivo. Sorafenib, but not sunitinib, inhibits function of DCs, characterized by reduced secretion of cytokines and expression of CD1a, major histocompatibility complex, and costimulatory molecules in response to TLR ligands as well as by their impaired ability to migrate and stimulate T-cell responses. These inhib…

NiacinamideSorafenibIndolesPyridinesImmunologyAntineoplastic AgentsApoptosisCD8-Positive T-LymphocytesPharmacologyBiologyurologic and male genital diseasesMajor histocompatibility complexT-Lymphocytes RegulatoryBiochemistryPeripheral blood mononuclear cellMiceImmune systemCell MovementIn vivoSunitinibmedicineAnimalsHumansCytotoxic T cellPyrrolesCells CulturedSunitinibPhenylurea CompoundsBenzenesulfonatesGranulocyte-Macrophage Colony-Stimulating FactorDextransDendritic CellsCell BiologyHematologySorafenibEndocytosisfemale genital diseases and pregnancy complicationsMice Inbred C57BLToll-Like Receptor 4biology.proteinCytokinesFemaleInterleukin-4Lymphocyte Culture Test MixedTyrosine kinaseCell DivisionSignal Transductionmedicine.drugBlood
researchProduct

Electrochemical sensor based on rGO/Au nanoparticles for monitoring H2O2 released by human macrophages

2021

Abstract Increased oxidative burden contributes to the pathogenesis of most inflammatory diseases and is associated with aging and chronic inflammation. Macrophages contribute to the generation of reactive oxygen species (ROS) within inflamed tissues. Currently, ROS generation is measured using fluorescent probes and colorimetric/fluorimetric biochemical assays. Hydrogen peroxide (H2O2) diffuses through the cell membrane and can be monitored in the extracellular space. Herein, we present a sensor for H2O2 detection released by cells in culture supernatants. H2O2 sensing performance was evaluated using chronoamperometric detection. A sensitivity of 0.0641 μA μM−1 cm−2 with a limit of detecti…

Nigericin02 engineering and technology010402 general chemistrymedicine.disease_cause01 natural sciencesFlow cytometrychemistry.chemical_compoundSettore ING-IND/17 - Impianti Industriali MeccaniciMaterials ChemistrymedicineExtracellularGold nanoparticlesViability assayElectrical and Electronic EngineeringInstrumentationGraphene oxidechemistry.chemical_classificationReactive oxygen speciesmedicine.diagnostic_testMacrophagesMetals and Alloys021001 nanoscience & nanotechnologyCondensed Matter PhysicsHydrogen peroxide0104 chemical sciencesSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialsSettore ING-IND/23 - Chimica Fisica ApplicatachemistryElectrochemical sensorCell cultureOxidative stressBiophysics0210 nano-technologyOxidative stressIntracellular
researchProduct

Dysidotronic acid, a new sesquiterpenoid, inhibits cytokine production and the expression of nitric oxide synthase.

2001

In a previous study, we reported a new bioactive sesquiterpenoid, named dysidotronic acid, to be a potent, selective human synovial phospholipase A(2) inhibitor. Dysidotronic acid is a novel, non-complex manoalide analogue lacking the pyranofuranone ring. We now investigate the effect of this compound on cytokine, nitric oxide and prostanoid generation on the mouse macrophage cell line RAW 264.7, where it showed a dose-dependent inhibition with inhibitory concentration 50% values in the micromolar range. This effect was also confirmed in the mouse air pouch injected with zymosan. Dysidotronic acid inhibited the production of tumor necrosis factor alpha and interleukin-1 beta as well as the …

Nitric oxide (NO)MouseLeukotriene B4NeutrophilsRAW 264.7Dysidotronic acidNitric Oxide Synthase Type IIDinoprostonePhospholipases ANitric oxideCell Linechemistry.chemical_compoundManoalideMicemedicineAnimalsHumansProstaglandin E2Enzyme InhibitorsCytokineNitritesPharmacologybiologyTumor Necrosis Factor-alphaMacrophagesZymosanZymosanMembrane ProteinsNitric oxide synthaseIsoenzymesAir pouchchemistryBiochemistryEnzyme inhibitorCyclooxygenase 2Prostaglandin-Endoperoxide Synthasesbiology.proteinCytokinesArachidonic acidDiterpenesNitric Oxide SynthaseSesquiterpenesmedicine.drugEuropean journal of pharmacology
researchProduct

Freeze-fracture features of epithelioid cells, multinucleated giant cells, and phagocytic macrophages

1987

The freeze-fracture morphology of epithelioid cells, multinucleated giant cells (Langhans' type), and phagocytic macrophages was investigated. The intensely folded and interdigitating surface membranes of epithelioid cells and multinucleated giant cells displayed no specialized areas of cell contact. The size of the intramembranous particles (IMP) and the fact that the area density of IMPs was higher in the cytoplasmic (P) faces than in the external (E) faces of the cell membranes agreed with observations in other eukaryotic cells. The area densities of the IMPs suggest lower transport rates of molecules across the cell membranes of granuloma cells than of certain epithelial cells. Small pi…

Nuclear EnvelopeLanghans giant cellBiologyEpitheliumCell membranemedicineAnimalsFreeze FracturingCell NucleusPhagocytesGranulomaNucleoplasmMacrophagesCell MembraneGranule (cell biology)Membrane ProteinsIntracellular MembranesRatsCell biologyCell nucleusmedicine.anatomical_structureGiant cellCytoplasmNephritis InterstitialLysosomesEpithelioid cellVirchows Archiv B Cell Pathology Including Molecular Pathology
researchProduct

Polymeric Selectin Ligands Mimicking Complex Carbohydrates: From Selectin Binders to Modifiers of Macrophage Migration

2016

Novel polymeric cell adhesion inhibitors were developed in which the selectin tetrasaccharide sialyl-LewisX (SLeX ) is multivalently presented on a biocompatible poly(2-hydroxypropyl)methacrylamide (PHPMA) backbone either alone (P1) or in combination with O-sulfated tyramine side chains (P2). For comparison, corresponding polymeric glycomimetics were prepared in which the crucial "single carbohydrate" substructures fucose, galactose, and sialic acid side chains were randomly linked to the PHPMA backbone (P3 or P4 (O-sulfated tyramine)). All polymers have an identical degree of polymerization, as they are derived from the same precursor polymer. Binding assays to selectins, to activated endo…

OligosaccharidesTyramine02 engineering and technologyLigands010402 general chemistry01 natural sciencesCatalysisFucoseInhibitory Concentration 50chemistry.chemical_compoundPolymethacrylic AcidsCell MovementHuman Umbilical Vein Endothelial CellsSide chainHumansTetrasaccharideMethacrylamideSialyl Lewis X AntigenCell adhesionCells CulturedMacrophagesGeneral ChemistrySurface Plasmon ResonanceFlow Cytometry021001 nanoscience & nanotechnologyIn vitro0104 chemical sciencesSialic acidMicroscopy Fluorescence MultiphotonNanomedicinechemistryBiochemistrySelectins0210 nano-technologySelectinAngewandte Chemie International Edition
researchProduct

Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer

2020

Abstract Background Immune response against cancer has prognostic impact but its role in gastric cancer is poorly known. The aim of the study was to assess the prognostic significance of immune cell score (CD3+, CD8+), tumour immune escape (PD-L1, PD-1) and immune tolerance (Clever-1). Methods After exclusion of Epstein-Barr virus positive (n = 4) and microsatellite instable (n = 6) tumours, the study included 122 patients with GC undergoing D2 gastrectomy. CD3+ and CD8+ based ICS, PD-L1, PD-1 and Clever-1 expressions were evaluated. Differences in survival were examined using Cox regression adjusted for confounders. The primary outcome was 5-year survival. Results The 5-year overall surviv…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyProgrammed Cell Death 1 ReceptorAdenocarcinomaArticleB7-H1 AntigenImmune toleranceImmunophenotyping03 medical and health sciences0302 clinical medicineImmunophenotypingImmune systemStomach NeoplasmsInternal medicinePD-L1medicineImmune ToleranceHumansAgedbiologyMolecular medicinebusiness.industryProportional hazards modelMacrophagesConfoundingImmunosurveillancemahasyöpäCancerennusteetMiddle Agedmedicine.diseaseOncologyimmuunivaste030220 oncology & carcinogenesisbiology.proteinsyöpätauditfenotyyppiFemaleTumor EscapebusinessCD8Signal TransductionBritish Journal of Cancer
researchProduct

Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy.

1990

Abstract purpose: A phase Ib/II clinical study was undertaken to assess the efficacy of recombinant human (rh) granulocyte-macrophage colony-stimulating (GM-CSF) factor in attenuating neutropenia and associated morbidity caused by high-dose anticancer chemotherapy administered in the presence or absence of autologous bone marrow support. patients and methods: Twenty-two patients with various solid tumors and lymphoid neoplasias were treated with a single daily subcutaneous dose of rh GM-CSF (250/μg/m 2 ) 48 hours after receiving a second cycle of highly myelotoxic chemotherapy for a period of 10 days. Within-subject comparisons on neutropenia-related clinical and laboratory variables were m…

OncologyAdultMalemedicine.medical_specialtyNeutropeniaTime FactorsAdolescentmedicine.drug_classNeutrophilsmedicine.medical_treatmentAntibioticsNeutropeniaLeukocyte CountColony-Stimulating FactorsBone MarrowInternal medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIn patientGrowth SubstancesAgedBone Marrow TransplantationChemotherapybusiness.industryCancerGranulocyte-Macrophage Colony-Stimulating FactorGeneral MedicineMiddle AgedAutologous bonemedicine.diseaseRecombinant ProteinsAnti-Bacterial AgentsGranulocyte macrophage colony-stimulating factorImmunologyToxicityDrug EvaluationFemalebusinessmedicine.drugAgranulocytosisThe American journal of medicine
researchProduct

Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX ch…

2013

The GOLFIG-2 phase III trial was designed to compare the immunobiological activity and antitumor efficacy of GOLFIG chemoimmunotherapy regimen with standard FOLFOX-4 chemotherapy in frontline treatment of metastatic colorectal cancer (mCRC) patients. This trial was conceived on the basis of previous evidence of antitumor and immunomodulating activity of the GOLFIG regimen in mCRC. GOLFIG-2 is a multicentric open/ label phase III trial (EUDRACT: 2005-003458-81). Chemo-naive mCRC patients were randomized in a 1:1 ratio to receive biweekly standard FOLFOX-4 or GOLFIG [gemcitabine (1000 mg/m 2, day 1); oxaliplatin (85 mg/m2, day 2); levofolinate (100 mg/m2, days 1-2), 5-fluorouracil (5-FU) (400…

OncologyMaleCancer ResearchGranulocyte-macrophage-colonystimulating- factorOrganoplatinum Compoundsmedicine.medical_treatmentLeucovorinColorectal NeoplasmGastroenterologyDeoxycytidineFOLFOXAldesleukinPhase iii trialAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyMedicineChemoimmunotherapyNeoplasm MetastasisAged 80 and overAldesleukinMiddle AgedNeoplasm MetastasiOxaliplatinColorectal carcinomaTreatment OutcomeFluorouracilFemaleFluorouracilColorectal NeoplasmsHumanmedicine.drugAdultmedicine.medical_specialtyImmunologyLymphocytes Tumor-InfiltratingChemoimmunotherapyInternal medicineHumansAgedPharmacologyChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryOrganoplatinum CompoundGranulocyte-Macrophage Colony-Stimulating FactorGemcitabineGemcitabineOxaliplatinRegimenInterleukin-2Neoplasm GradingbusinessJournal of immunotherapy (Hagerstown, Md. : 1997)
researchProduct

Effect of Treatment with rhGM-CSF and Low-Dose Cytosine Arabinoside on Leukemic Blast Cells in Patients with Myelodysplastic Syndromes

1990

Treatment of patients having myelodysplastic a syndromes (MDS) with approaches such as differentiation induction, single cytostatic agents or supportive care only has, up to now, been rather unsuccessful. Aggressive chemotherapy followed by bone marrow transplantation is only suitable for a very small proportion of patients. Thus, there is a need for new therapeutic alternatives.

Oncologymedicine.medical_specialtyAcute myeloblastic leukemiabusiness.industryCellular differentiationmedicine.medical_treatmentMyelodysplastic syndromesmedicine.diseaseLeukemiaGranulocyte macrophage colony-stimulating factorCytokineInternal medicinePrecursor cellImmunologyCytarabineMedicinebusinessmedicine.drug
researchProduct

Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Neutropenia and Related Morbidity Induced by Myelotoxic Chemotherapy

1990

Myelosuppression-related neutropenia is the major side effect of most anticancer chemotherapy. Despite considerable improvements in supportive care due to the advent of a variety of new antibiotic combinations, infection remains the main risk arising during the neutropenic period that follows intensive chemotherapy for cancer [1]. In addition, neutropenia is the major obstacle to dose escalation, frequency of cytoreductive treatment, and thus to improved cancer control. Regarding reduction of the period of neutropenia and increase of the maximum tolerated dose of effective anticancer agents, autologous bone marrow transplantation (ABMT) has recently offered new promise. However, as many as …

Oncologymedicine.medical_specialtyChemotherapySide effectbusiness.industrymedicine.medical_treatmentCancerImmunotherapyNeutropeniamedicine.diseaseColony-stimulating factorLeukemiaGranulocyte macrophage colony-stimulating factorInternal medicineImmunologymedicinebusinessmedicine.drug
researchProduct